Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor (VMT2), is reported to significantly improve chorea and be well tolerated in the randomized, double-blind, placebo-controlled KINECT-HD trial[111] (NCT04102579) including 64 patients using valbenazine and 61 patients using placebo for 12 weeks. This evidence concerns the gene SLC18A2 and choreatic disease.